Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report issued on Saturday, Wall Street Zen reports.
AMRX has been the subject of several other reports. JPMorgan Chase & Co. raised their target price on Amneal Pharmaceuticals from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 4th. Weiss Ratings lowered shares of Amneal Pharmaceuticals from a “buy (b)” rating to a “hold (c+)” rating in a report on Tuesday, November 10th. Oppenheimer initiated coverage on shares of Amneal Pharmaceuticals in a research note on Wednesday, September 23rd. They issued an “outperform” rating and a $27.00 price objective for the company. The Goldman Sachs Group restated a “buy” rating and issued a $24.00 price objective on shares of Amneal Pharmaceuticals in a research note on Thursday, October 29th. Finally, Leerink Partners raised their price objective on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th. Eight investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.
View Our Latest Stock Report on Amneal Pharmaceuticals
Amneal Pharmaceuticals Stock Performance
Amneal Pharmaceuticals stock opened at $21.38 on Friday. The business has a 50 day moving average price of $19.71 and a two-hundred day moving average price of $16.11. The company has a quick ratio of 1.24, a current ratio of 1.87 and a debt-to-equity ratio of 5.61. Amneal Pharmaceuticals has a 12 month low of $11.39 and a 12 month high of $22.07. The stock has a market cap of $7.45 billion, a price-to-earnings ratio of 50.90, a price-to-earnings-growth ratio of 2.43 and a beta of 1.24.
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.03. The company had revenue of $862.68 million for the quarter. Amneal Pharmaceuticals had a return on equity of 283.50% and a net margin of 4.17%. As a group, equities analysts forecast that Amneal Pharmaceuticals will post 0.98 EPS for the current year.
Institutional Investors Weigh In On Amneal Pharmaceuticals
Large investors have recently modified their holdings of the stock. FORA Capital LLC acquired a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $260,000. Empowered Funds LLC bought a new position in shares of Amneal Pharmaceuticals during the 3rd quarter worth approximately $2,366,000. First Trust Advisors LP boosted its stake in Amneal Pharmaceuticals by 55.6% in the 3rd quarter. First Trust Advisors LP now owns 955,599 shares of the company’s stock valued at $19,246,000 after buying an additional 341,393 shares in the last quarter. Public Sector Pension Investment Board boosted its stake in Amneal Pharmaceuticals by 73.4% in the 3rd quarter. Public Sector Pension Investment Board now owns 1,026,235 shares of the company’s stock valued at $20,032,000 after buying an additional 434,400 shares in the last quarter. Finally, Global Retirement Partners LLC boosted its stake in Amneal Pharmaceuticals by 42.6% in the 3rd quarter. Global Retirement Partners LLC now owns 25,815 shares of the company’s stock valued at $520,000 after buying an additional 7,706 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals is a U.S.-based pharmaceutical company that develops, manufactures and markets generic and specialty medicines. Its products include a broad range of generic drugs, including complex formulations and injectable medicines, as well as branded therapies in areas such as neurology and endocrinology. The company also operates AvKARE, which distributes pharmaceuticals and medical products to government, institutional and commercial customers. Amneal serves customers in the United States and in international markets.
Further Reading
- Five stocks we like better than Amneal Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
